Sunday 22 December 2024

The Pharma Letter Podcast — Episode 20 — Galapagos update—with CEO Paul Stoffels

Biotechnology
Simon Wentworth
2 February 2023
2-2

More on this story...

Biotechnology
R&D U-turn sees Galapagos ditching liver and kidney programs
4 November 2022
Biotechnology
Belgian biotech Galapagos goes on a spending spree
22 June 2022
Biotechnology
NICE recommends Galapagos' Jyseleca in UC
1 June 2022
Biotechnology
Strategic overhaul continues apace at Galapagos, with new R&D deal
31 March 2023


Companies featured in this story

More ones to watch >


Today's issue

The week in pharma: action, reaction and insight – week to December 20
Pharmaceutical
The week in pharma: action, reaction and insight – week to December 20
22 December 2024
Biotechnology
FDA approves Novo Nordisk’s Alhemo
22 December 2024
Pharmaceutical
Italfarmaco’s Duvyzat backed by MHRA
22 December 2024
Pharmaceutical
Neurocrine Biosciences launches Crenessity in USA
20 December 2024
Biotechnology
Epitopea teams up with Genevant in $124 million deal
20 December 2024
Biotechnology
Mixed results for GSK’s Zejula/Jemperli combo
20 December 2024
Biotechnology
Regeneron advances anticoagulant antibody program
20 December 2024

Company Spotlight

Australian regenerative medicine company Mesoblast (ASX: MSB) is developing biotherapeutics based on its proprietary cell-based technologies.




More Features in Biotechnology

FDA approves Novo Nordisk’s Alhemo
22 December 2024
Epitopea teams up with Genevant in $124 million deal
20 December 2024
Mixed results for GSK’s Zejula/Jemperli combo
20 December 2024
Regeneron advances anticoagulant antibody program
20 December 2024


Copyright © The Pharma Letter 2024   |   Headless Content Management with Blaze